Amphotericin B colloidal dispersion: an effective drug for the treatment of mucormycosis in China

• DOI: 10.3389/fcimb.2023.1147624
• Publication Date: 2023-05-17T05:37:32Z
• Authors: Juntao Liu; Xiaoxu Ma
• Keywords: White blood cell

Mucormycosis has emerged as an increasingly important cause of morbidity and mortality in immunocompromised patients, but the effective drugs for treatment are limited. Hence, study aimed to summarize characteristics mucormycosis patients with hematological malignancies, investigate efficacy safety Amphotericin B Colloidal Dispersion (ABCD) treating mucormycosis.In this study, complicated by malignancies who received ABCD at First Affiliated Hospital Zhengzhou University from April 2021 May 2022 were retrospectively enrolled. The clinical data enrolled collected, then, drug response 2 weeks, 4 end treatment; survival rate 4, 8, 12 weeks; laboratory-related indicators adverse events (AEs) associated evaluated.In total, 9 main symptoms fever, cough, chest pain. In addition, reversed halo signs (RHS) found on CTs. responses 100% (9/9), 77.8% (7/9), respectively. rates weeks 66.7% (6/9), Among indicators, white blood cell (WBC) counts significantly increased baseline after 1 (P<0.05), whereas neutrophil only post-treatment (P<0.05). most common AEs infusion-related manifesting chills, pruritus. Moreover, none suffered renal injury once again.ABCD is a promising strategy hematologic showing remarkable safety.